The Biopharmaceutical Market Worldwide Will Be Worth Nearly One Trillion USD by 2030
The Global Biopharmaceutical Market is anticipated to be valued at almost $1 trillion USD by 2030 (As stated by Statista 2023). As chronic diseases like cancer, diabetes, and heart disease are becoming more prevalent around the world, there is a surge in demand for biologics, which is one of the main factors fueling the growth of the biologics manufacturing market. Accelerated technological developments for biologics and favorable government regulations are other main drivers supporting the growth of the pharma market research companies.
Increased R&D spending has also led to new drug discoveries that can only be produced by specific methods available through biotechnology-based companies. Governments all over the world are offering incentives to companies that invest in creating novel therapies for rare diseases. This encourages more investment in this area and increases demand for the specialized production skills provided by biotech companies. By enabling quicker development timeframes and lowering manufacturing process costs, technological advancements are giving businesses greater options when it comes to satisfying client needs at affordable prices without compromising quality standards.
North America is the Most Dominating Market in the Biopharma Manufacturing Market
The market for producing biologics is dominated by North America, with Europe and Asia Pacific coming in second and third. The US and Canada are the biggest contributors to this regional market due to their substantial presence in terms of research & development, government backing, and sophisticated healthcare infrastructure. Fujifilm Diosynth Biotechnologies, Amgen, Patheon Pharma Services, AbbVie Contract Manufacturing Organization, Catalent, and Thermo Fisher Scientific are a few of the key companies in the area.
North America will experience tremendous growth as a result of the region’s extensive network of CMO production facilities and robust regulatory environment. Government funding of R&D initiatives has also made it possible for businesses to create innovative drugs more quickly than their competitors in other regions of the world.
Biologics Outsourcing is a Major Trend in the Biopharma Industry
Pharmaceutical market research companies are outsourcing the production of their biologics to skilled contract manufacturers due to their ability to produce biologics on a large scale. Some CMOs have resources and skills that pharmaceutical companies don’t have in-house and are experts in manufacturing biologics. Additionally, by using contract manufacturing services, drug companies can quickly launch new products without the long lead times involved in starting an internal operation from scratch or upgrading the existing facilities with the most recent technology or regulations. Third-party sourcing also reduces the regulatory associated concerns involved in developing the biologics internally. Small biotech firms that struggle to manufacture their products internally—particularly complicated downstream processing that requires specialized instrumentation—outsource their operations to other manufacturers.
Intensification of Existing Manufacturing Processes Will be Essential
Biopharmaceutical producers are under more strain due to rising demand and competition. To successfully navigate the current market environment, existing manufacturing processes will need to be intensified. Utilizing processing methods that promote rapidity, high throughput, and effective use of facility space will be important for manufacturers. As a result of this pressure, manufacturers will be implementing more rigorous methods. Companies will increasingly use continuous flow systems, single-use technologies, and high-tech expression systems. Flexibility will also be crucial to the operations of biopharma manufacturing on a bigger scale. Manufacturers’ ability to quickly build new facilities will help them become more flexible on a business level. Also, manufacturing companies are likely to increase their productivity by expanding global capacity and optimizing manufacturing processes. The industry will see more partnerships between manufacturers and international partners for increased business flexibility.
Growing Bioprocessing Facilities in Asia-Pacific
The market for biopharmaceutical contract manufacturing is expanding primarily as a result of rising biologics demand and expanding outsourcing by pharmaceutical firms in Asia-Pacific. China has developed significant biomanufacturing capabilities, and regulatory improvements have enabled China to develop biologics that meet the standards required by both the CFDA and the FDA.
IMAPAC is a one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. IMAPAC offers solutions for market research for biopharmaceutical companies, including biopharma industry reports, real-time visualization data trackers, and customized services. Our research methodology involves market research survey companies with industry experts to collect quality and validated information. Biopharma industry leaders are using market intelligence to grow in the industry rapidly.
We have put together data for more than 730 bioprocessing facilities that are operating in the Asia-Pacific region by biotech companies, pharmaceuticals, and CMO/CDMOs. The data is covered across several parameters to provide updated insights into the bioprocessing industry, such as the locations of the biologics facilities, the production capacity of Biopharma and CMO/CDMOs in APAC, upstream and downstream processing capabilities, analytical equipment and technologies, and exclusive information on company’s future plans and investment. The data provides an in-depth overview of the upcoming competition in the Asian Bioprocessing market and aims to assist organizations in keeping track of their competitors, identify any opportunities for collaboration or investments for the development or manufacturing of large molecules in the Asia-Pacific region, aiding in key strategic decisions for the biopharma business industry.